Leqembi – Implications for Health Insurance Payers: A Comprehensive Analysis

Introduction

On July 6, 2023, the FDA granted full traditional approval to Lecanemab (Leqembi), marking a significant milestone as the first disease-modifying treatment for Alzheimer’s disease to receive standard approval. This analysis examines the broader Leqembi payer implications for health insurance organizations, offering data-driven insights into Medicare coverage frameworks, clinical utilization protocols, and financial considerations.

CMS Coverage and Leqembi Payer Implications

The Centers for Medicare & Medicaid Services (CMS) have announced the coverage of Leqembi through Medicare. However, this coverage is contingent upon the collection of patient data as part of a disease registry. CMS has taken steps to remove barriers by establishing the Alzheimer’s Disease CED Study Registry, facilitating the implementation of this coverage.

Eligibility Criteria and Market Potential

Leqembi is suitable for patients with mild cognitive impairment and mild dementia caused by Alzheimer’s disease, collectively called early-stage Alzheimer’s disease. Approximately 1.5 million people in the United States fall within this eligibility range. However, it is important to note that a larger population of approximately five million individuals has progressed beyond the scope of Leqembi’s eligibility. Consequently, an estimated 3% of Medicare beneficiaries may be eligible for this drug, which comes at an annual cost of $26,500.

Significant Side Effects and Risk Considerations

Leqembi carries several notable black box warnings, with one of the most common side effects being ARIA (Amyloid related imaging abnormalities). Patients who are ApoE4 homozygous (carriers of two copies of the ApoE4 allele) likely face an increased risk of ARIA. Although ARIA is usually asymptomatic and occurs early in treatment, serious and life-threatening events such as edema and brain bleeds are rare but possible. Given these risks, prescribing Leqembi and similar anti-amyloid drugs should be limited to Alzheimer’s-experienced specialists, which in most cases is a Cognitive/Behavioral Neurologist. A comprehensive vetting process involving an MRI scan, confirmed beta-Amyloid pathology, and an ApoE4 status test should be followed (or at least strongly encouraged), with a thorough risk-benefit discussion with the patient.

Challenges in Supply and Patient Acceptance

Behavioral neurologists specializing in this field are in short supply, leading to extended waiting times of over 10 months. Additionally, both patients and healthcare professionals will require time to become acquainted with the medication and its protocols before widespread use can be expected. These factors, combined with the significant risks involved, may deter a considerable proportion of patients from pursuing Leqembi as a treatment option.

Cost Implications and Potential Savings

Considering all the aforementioned factors, it is projected that less than 1% of Medicare beneficiaries will seek access to Leqembi within the next year. As a result, the additional cost, including diagnostic workup expenses, is estimated to be less than $150 USD per year per average Medicare beneficiary.

However, it is essential to recognize the potential medical cost savings resulting from delaying cognitive decline. These savings are estimated to be up to $4,000 per member receiving the medication per year, translating to an average of $60 per Medicare member.

Furthermore, the introduction of disease-modifying therapy is expected to close coding gaps for dementia diagnosis, as currently 60% of cases go undiagnosed. The availability of Leqembi and the increased media attention surrounding it are likely to enhance willingness to undergo testing and receive a diagnosis. With a risk adjustment benefit of $3,000 to $5,000 per diagnosed member per year, even a modest 5% increase in diagnosis rates could result in a $20 revenue increase per member for Medicare Advantage plans.

Anticipated Coverage by Medicare Advantage Plans

Following CMS guidance, commercial and Medicare Advantage plans have established clinical step-up criteria and prior authorization protocols for Leqembi. Because proper prescribing requires confirmation of amyloid pathology and ongoing MRI safety monitoring for ARIA, risk-bearing organizations rely on structured specialist networks to ensure therapy is delivered safely and cost-effectively.

Partnering with Isaac Health for Clinical Governance

Isaac Health partners directly with health plans, Medicare Advantage organizations, and ACOs to establish evidence-based dementia care pathways and streamlined prior authorization. To explore our health plan partnerships, review our [clinical outcomes and evidence](https://isaac.health/evidence/), read our [actuarial assessment on RAF scores](https://isaac.health/raf-assessment/), or [contact our clinical partnerships team](https://isaac.health/contact/) to schedule an executive consultation.

Conclusion

The full approval of Leqembi marks a groundbreaking development in Alzheimer’s treatment. As health insurance employees, understanding the implications of this approval is vital for effective coverage decisions. By considering the eligibility criteria, potential cost implications, risk factors, and anticipated coverage by Medicare Advantage plans, health insurance payers can navigate the challenges associated with Leqembi’s introduction and ensure appropriate patient access to this significant disease-modifying therapy.